These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 805816)

  • 21. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracts of airborne grain dusts activate alternative and classical complement pathways.
    Olenchock SA; Mull JC; Major PC
    Ann Allergy; 1980 Jan; 44(1):23-8. PubMed ID: 6766283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The septic burned patient: a model for studying the role of complement and immunoglobulins in opsonization of opportunist micro-organisms.
    Bjornson AB; Altemeier WA; Bjornson HS
    Ann Surg; 1979 Apr; 189(4):515-27. PubMed ID: 109057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human glomerulonephritis and the C3 nephritic factor (C3NeF).
    Berthoux FC; Carpenter CB; Freyria AM; Traeger J; Merrill JP
    Clin Nephrol; 1976 Mar; 5(3):93-100. PubMed ID: 57022
    [No Abstract]   [Full Text] [Related]  

  • 25. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
    Brade V; Bentley C; Bitter-Suermann D; Hadding U
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo decomplementation of guinea pigs with cobra venom factor and anti-C3 serum: analysis of the requirement of C3 and C5 for the mediation of endotoxin-induced death.
    Drake WP; Pokorney DR; Kopyta LP; Mardiney MR
    Biomedicine; 1976 May; 25(3):91-4. PubMed ID: 949521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae.
    Ingwer I; Petersen BH; Brooks G
    J Lab Clin Med; 1978 Aug; 92(2):211-20. PubMed ID: 98602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Specific measurement of alternate pathway activation of complement in human glomerulonephritides (GN): 125 cases (author's transl)].
    Berthoux FC; Freyria AM
    Nephrologie; 1980; 1(2):61-6. PubMed ID: 7301022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptors for C3 on rat peritoneal mast cells.
    Sher A; McIntyre SL
    J Immunol; 1977 Aug; 119(2):722-5. PubMed ID: 407303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of Giardia lamblia trophozoites to the lethal effect of human serum.
    Hill DR; Burge JJ; Pearson RD
    J Immunol; 1984 Apr; 132(4):2046-52. PubMed ID: 6699407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A complement C3 fragment equivalent to mammalian C3d from the common carp (Cyprinus carpio): generation in serum after activation of the alternative pathway and detection of its receptor on the lymphocyte surface.
    Nakao M; Miura C; Itoh S; Nakahara M; Okumura K; Mutsuro J; Yano T
    Fish Shellfish Immunol; 2004 Feb; 16(2):139-49. PubMed ID: 15123318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions of the classical and alternate complement pathway with endotoxin lipopolysaccharide. Effect on platelets and blood coagulation.
    Kane MA; May JE; Frank MM
    J Clin Invest; 1973 Feb; 52(2):370-6. PubMed ID: 4683877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of ethyleneglycoltetra-acetic acid on bactericidal activity of human serum against Escherichia coli.
    Roberts AP; Phillips R
    J Med Microbiol; 1981 May; 14(2):195-203. PubMed ID: 6785440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Properdin deficiency in a family with fulminant meningococcal infections.
    Sjöholm AG; Braconier JH; Söderström C
    Clin Exp Immunol; 1982 Nov; 50(2):291-7. PubMed ID: 7151327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of factor B and C3 in guinea pig serum by zymosan or by activated properdin depends on the presence of factor D.
    Brade V; Bentley C; Kossorotow A; Bitter-Suermann D
    Monogr Allergy; 1977; 12():83-5. PubMed ID: 917024
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the effect of various antisera and cobra venom factor on inflammatory reactions in guinea-pig skin. II. The Arthus reaction and the local Shwartzman reaction.
    Lewis E; Turk JL
    J Pathol; 1975 Feb; 115(2):111-25. PubMed ID: 125318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma therapy of primary rat mammary carcinoma: dependence of consumption of C3 during absorption of plasma with sepharose derivatives on the anticoagulant.
    Nakanishi K; Zbar B; Borsos T
    Cancer Res; 1985 Sep; 45(9):4122-7. PubMed ID: 3928150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.